Loading clinical trials...
Loading clinical trials...
Bilateral rTMS Clinical Trial for Persistent Auditory Hallucinations Results for a Terminated Study
The primary purpose of this study was to conduct fMRI neuroimaging studies prior to and subsequent to the rTMS intervention. The intent was to ascertain changes in regional brain activation and connectivity that most robustly predict level of improvement in auditory hallucinations elicited by bilateral rTMS as assessed by the primary outcome variables.
This study is an extension of previous clinical trials (NCT00308997 and NCT00567281) that were initiated in 2006. This study record provides the results for the amended study NCT00567281 (originally called a 'third arm') that was discontinued following the passing of Dr. Ralph Hoffman. The primary purpose of the study was to conduct fMRI neuroimaging studies prior to and subsequent to the rTMS intervention. The intent was to ascertain changes in regional brain activation and connectivity that most robustly predict level of improvement in auditory hallucinations elicited by bilateral rTMS as assessed by our primary outcome variables. It was hoped that this combined fMRI/rTMS study would provide critical new insights into the neurobiological basis of auditory hallucinations. The results presented are what was summarized following Dr. Hoffman's passing and were compiled by Dr. Philip Corlett.
Age
18 - 55 years
Sex
ALL
Healthy Volunteers
No
Department of Psychiatry, Yale School of Medicine
New Haven, Connecticut, United States
Start Date
September 1, 2012
Primary Completion Date
October 1, 2016
Completion Date
October 1, 2016
Last Updated
October 30, 2020
15
ACTUAL participants
Magstim Rapid 2 system triggering Magstim Super Rapid system
DEVICE
Lead Sponsor
Yale University
Collaborators
NCT07455929
NCT06740383
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions